Download PDF
Kardiologie up2date 2008; 4(4): 333-343
DOI: 10.1055/s-2008-1077708
Risikofaktoren

© Georg Thieme Verlag KG Stuttgart · New York

Nutzen und Risiken oraler Antidiabetika hinsichtlich kardialer Endpunkte

Nikolaus  Marx
Further Information

Publication History

Publication Date:
30 December 2008 (online)

Also available at
    Permissions and Reprints All articles of this category

Abstract

The reduction of cardiovascular risk in patients with type 2 diabetes poses a major challenge in internal medicine these days. The present review will focus on the role of glucose lowering therapies in this context and in particular elucidate the effect of oral anti-diabetic drugs on cardiovascular morbidity and mortality.

Kernaussagen

  • Patienten mit einem Diabetes mellitus haben ein erhöhtes Risiko für die Entstehung einer koronaren Herzerkrankung mit ihren Folgen einer instabilen Angina pectoris und eines akuten Myokardinfarkts.

  • Eine strenge Blutzuckersenkung alleine führt im Zeitraum bis zu 5 Jahren nicht zu einer signifikanten Reduktion kardiovaskulärer Mortalität und Morbidität.

  • Metformin reduzierte in der Subgruppe übergewichtiger Patienten in der UKPDS-Studie die Myokardinfarkthäufigkeit.

  • Pioglitazon verminderte in der PROactive-Studie bei Patienten mit Diabetes mellitus Typ 2 in der Sekundärprävention den „principal secondary endpoint” von Tod, Infarkt und Schlaganfall.

Ein kombinierter Therapieansatz mit strenger Einstellung der Lipide und des Blutdrucks, der Gabe von Aspirin und der zusätzlichen Applikation von ACE-Hemmern oder AT1-Rezeptor-Antagonisten können das Risiko makrovaskulärer Ereignisse bei Typ-2-Diabetikern nachhaltig reduzieren.

Literatur

  • 1 Haffner S M, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.  N Engl J Med. 1998;  339 229-234
    CrossrefPubMedGoogle Scholar
  • 2 Schramm T K, Gislason G H, Kober L. et al . Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people.  Circulation. 2008;  117 1945-1954
    CrossrefPubMedGoogle Scholar
  • 3 Stratton I M, Adler A I, Neil H A. et al . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.  BMJ. 2000;  321 405-412
    CrossrefPubMedGoogle Scholar
  • 4 Uk P. Intensive blood-glucose control with sulfonureas or insulin compared with conventional treatment and risk of complications in patients with type II diabetes.  Lancet. 1998;  352 837-853
    CrossrefPubMedGoogle Scholar
  • 5 Patel A, MacMahon S, Chalmers J. et al . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.  N Engl J Med. 2008;  358 2560-2572
    CrossrefPubMedGoogle Scholar
  • 6 Gerstein H C, Miller M E, Byington R P. et al . Effects of intensive glucose lowering in type 2 diabetes.  N Engl J Med. 2008;  358 2545-2559
    CrossrefPubMedGoogle Scholar
  • 7 Dluhy R G, McMahon G T. Intensive glycemic control in the ACCORD and ADVANCE trials.  N Engl J Med. 2008;  358 2630-2633
    CrossrefPubMedGoogle Scholar
  • 8 Kar P, Holt R I. The Effect of Sulphonylureas on the Microvascular and Macrovascular Complications of Diabetes.  Cardiovasc Drugs Ther. 2008;  22 207-213
    CrossrefPubMedGoogle Scholar
  • 9 Leibowitz G, Cerasi E. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?.  Diabetologia. 1996;  39 503-514
    PubMedGoogle Scholar
  • 10 Lazdunski M. Ion channel effects of antidiabetic sulfonylureas.  Horm Metab Res. 1996;  28 488-495
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Meinert C L, Knatterud G L, Prout T E, Klimt C R. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results.  Diabetes. 1970;  19 (Suppl) 789-830
    PubMedGoogle Scholar
  • 12 Bailey C J, Turner R C. Metformin.  N Engl J Med. 1996;  334 574-579
    CrossrefPubMedGoogle Scholar
  • 13 UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).  Lancet. 1998;  352 854-865
    CrossrefPubMedGoogle Scholar
  • 14 Johnson J A, Majumdar S R, Simpson S H, Toth E L. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.  Diabetes Care. 2002;  25 2244-2248
    CrossrefPubMedGoogle Scholar
  • 15 Eurich D T, McAlister F A, Blackburn D F. et al . Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review.  BMJ. 2007;  335 497
    CrossrefPubMedGoogle Scholar
  • 16 Schmidt D D, Frommer W, Junge B. et al . Alpha-Glucosidase inhibitors. New complex oligosaccharides of microbial origin.  Naturwissenschaften. 1977;  64 535-536
    CrossrefPubMedGoogle Scholar
  • 17 van de Laar F A, Lucassen P L, Akkermans R P. et al . Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis.  Diabetes Care. 2005;  28 154-163
    CrossrefPubMedGoogle Scholar
  • 18 Chiasson J L, Josse R G, Gomis R. et al . Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.  Lancet. 2002;  359 2072-2077
    CrossrefPubMedGoogle Scholar
  • 19 Chiasson J L, Josse R G, Gomis R. et al . Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.  JAMA. 2003;  290 486-494
    CrossrefPubMedGoogle Scholar
  • 20 Hanefeld M, Schaper F. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits.  Expert Rev Cardiovasc Ther. 2008;  6 153-163
    CrossrefPubMedGoogle Scholar
  • 21 Marx N, Duez H, Fruchart J C, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.  Circ Res. 2004;  94 1168-1178
    CrossrefPubMedGoogle Scholar
  • 22 Marx N, Froehlich J, Siam L. et al . The antidiabetic PPARg-activator rosiglitazone reduces MMP-9 serum levels in type-2 diabetic patients with coronary artery disease.  Arterioscl Thromb Vasc Biol. 2003;  23 283-288
    CrossrefPubMedGoogle Scholar
  • 23 Mazzone T, Meyer P M, Feinstein S B. et al . Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.  JAMA. 2006;  296 2572-2581
    CrossrefPubMedGoogle Scholar
  • 24 Sidhu J S, Cowan D, Kaski J C. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients.  J Am Coll Cardiol. 2003;  42 1757-1763
    CrossrefPubMedGoogle Scholar
  • 25 Dormandy J A, Charbonnel B, Eckland D JA. et al . Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.  Lancet. 2005;  366 1279-1289
    CrossrefPubMedGoogle Scholar
  • 26 Holman R R, Retnakaran R, Farmer A, Stevens R. PROactive study.  Lancet. 2006;  367 25-26; author reply 26 – 27
    CrossrefPubMedGoogle Scholar
  • 27 Home P D, Pocock S J, Beck-Nielsen H. et al . Rosiglitazone Evaluated for Cardiovascular Outcomes – An Interim Analysis.  N Engl J Med. 2007;  357 28-38
    CrossrefPubMedGoogle Scholar
  • 28 Nissen S E, Wolski K. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes.  N Engl J Med. 2007;  356 2457-2471
    CrossrefPubMedGoogle Scholar
  • 29 Singh S, Loke Y K, Furberg C D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.  JAMA. 2007;  298 1189-1195
    CrossrefPubMedGoogle Scholar
  • 30 Lago R M, Singh P P, Nesto R W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.  Lancet. 2007;  370 1129-1136
    CrossrefPubMedGoogle Scholar
  • 31 McAfee A T, Koro C, Landon J, Ziyadeh N, Walker A M. Coronary heart disease outcomes in patients receiving antidiabetic agents.  Pharmacoepidemiol Drug Saf. 2007;  16 711-725
    CrossrefPubMedGoogle Scholar
  • 32 Nauck M. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.  Diabet Med. 1996;  13 S39-S43
    PubMedGoogle Scholar
  • 33 Gaede P, Vedel P, Larsen N. et al . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.  N Engl J Med. 2003;  348 383-393
    Google Scholar
  • 34 Gaede P, Lund-Andersen H, Parving H H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes.  N Engl J Med. 2008;  358 580-591
    CrossrefPubMedGoogle Scholar

Prof. Dr. med. Nikolaus Marx

Klinik für Innere Medizin II
Medizinische Universitätsklinik Ulm

Albert-Einstein-Allee 23
89081 Ulm

Email: nikolaus.marx@uniklinik-ulm.de

      >